22:46:11 EST Sat 02 Mar 2024
Enter Symbol
or Name
USA
CA



News for U:BXRX from 2023-03-02 to 2024-03-01 - 16 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-10-18 08:00U:BXRXNews ReleaseBaudax Bio Announces Corporate Update
2023-09-28 08:00U:BXRXNews ReleaseBaudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
2023-09-07 08:00U:BXRXNews ReleaseBaudax Bio to Participate in the H.C. Wainwright Global Investment Conference
2023-08-23 08:00U:BXRXNews ReleaseBaudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
2023-08-17 08:00U:BXRXNews ReleaseBaudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
2023-08-16 08:00U:BXRXNews ReleaseBaudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-06-30 08:00U:BXRXNews ReleaseBaudax Bio Acquires TeraImmune, Inc.
2023-06-07 09:21U:BXRXNews ReleaseBaudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
2023-06-06 09:00U:BXRXNews ReleaseBaudax Bio Announces Date of Reconvened Annual Meeting
2023-05-12 08:33U:BXRXNews ReleaseBaudax Bio Reports First Quarter Financial Results and Provides Business Update
2023-05-03 16:05U:BXRXNews ReleaseBaudax Bio to Present at the Sidoti Virtual Investor Conference
2023-05-01 17:43U:BXRXNews ReleaseBaudax Bio Announces Closing of $4 Million Public Offering
2023-04-26 21:15U:BXRXNews ReleaseBaudax Bio Announces Pricing of $4 Million Public Offering
2023-04-25 08:00U:BXRXNews ReleaseBaudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
2023-04-24 16:30U:BXRXNews ReleaseBaudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
2023-03-27 08:00U:BXRXNews ReleaseBaudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000